Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial

Table 3 Blood parameter, treatment dose and variability (MSSD) of Period 3–4 (Q2W ESAs administration interval)

	C.E.R.A	Darbepoetin alfa	p-value
	(n = 19)	(n = 19)	p-value
Hemoglobin, g/dl (mean, SD)	11.6 (0.6)	11.4 (0.6)	0.24
Reticulocyte count, cells/μl (mean, SD)	78915 (20625)	72765 (18220)	0.34
Ferritin, μg/l (mean, SD)	433.2 (105.3)	478.9 (98.3)	0.18
Cumulated ESA dose, μg (mean, SD)	895 (657.7)	865.6 (622.9)	0.89
Cumulated iron dose, μg (mean, SD)	712.5 (272.9)	611.1 (286.7)	0.30
ST-MSSD Hb, g ² /dl ² (mean, SD)	0.52 (0.40)	0.67 (0.45)	0.28
LT-MSSD Hb, g ² /dl ² (mean, SD)	1.25 (1.10)	1.01 (1.24)	0.54
ST-MSSD Ret, cells ² /μl ² (mean, SD)	16.5x10⁸ (14.4x10⁸)	20.3x10⁸ (20.5x10⁸)	0.52
LT-MSSD-Ret , cells ² /μl ² (mean, SD)	12.1x10⁸ (15.5x10⁸)	6.9x10⁸ (9.7 x10⁸)	0.24

ISSN: 1471-2369